Cover Image
市場調查報告書

逆流性食道炎(胃食道逆流症):開發平台分析

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232845
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
逆流性食道炎(胃食道逆流症):開發平台分析 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 77 Pages
簡介

胃液逆流到食道就稱之為胃食道逆流症(GERD),症狀有噁心、胃灼熱、嘔吐等。造成下食道括約肌(LES)開關失常的過度飲食、肥胖、懷孕、過油食物、部分醫藥品都是致病因子。

本報告函括全球逆流性食道炎(胃食道逆流症)治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

逆流性食道炎(胃食道逆流症)概要

治療藥的開發

  • 逆流性食道炎(胃食道逆流症)開發中產品:概要
  • 逆流性食道炎(胃食道逆流症)開發中產品:比較分析

逆流性食道炎(胃食道逆流症):開發中的治療藥:各企業

逆流性食道炎(胃食道逆流症):開發中的治療藥:大學·研究機關別

逆流性食道炎(胃食道逆流症):開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

逆流性食道炎(胃食道逆流症):開發中的產品:各企業

逆流性食道炎(胃食道逆流症):開發中的產品:大學·研究機關別

逆流性食道炎(胃食道逆流症):治療藥的開發企業

  • Ahn-Gook Pharmaceutical Co., Ltd.
  • aRigen Pharmaceuticals, Inc.
  • Cempra, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • RaQualia Pharma Inc.
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • Vecta Ltd.
  • Wockhardt Limited
  • Yuhan Corporation
  • Yuyu Pharma, Inc.

逆流性食道炎(胃食道逆流症):治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ARH-1029
  • cobiprostone
  • DWJ-1367
  • E-3710
  • Esomeprazole鎂
  • G-17DT
  • IW-3718
  • JNJ-26070109
  • omepurazoru
  • pantopurazoru
  • RQ-00000004
  • RQ-00000774
  • 消化性潰瘍治療藥
  • GERD及糖尿病性胃輕癱細葉冬青磷受體抑制劑
  • 消化器官疾病質子幫浦抑制劑
  • SSP-002358
  • tenatopurazoru
  • YH-4808
  • YY-DXR
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9527IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 5 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
    • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
    • Ahn-Gook Pharmaceutical Co Ltd
    • Cempra Inc
    • Daewoong Pharmaceutical Co Ltd
    • Eisai Co Ltd
    • Ilyang Pharmaceutical Co Ltd
    • Ironwood Pharmaceuticals Inc
    • Jeil Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Takeda Pharmaceutical Company Ltd
    • Wockhardt Ltd
    • Yooyoung Pharm Co Ltd
    • Yuyu Pharma Inc
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
    • (lansoprazole + omeprazole) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceclazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEM-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexlansoprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-14012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-3710 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-17DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ilaprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-3718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-1366 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tegoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenatoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YY-DXR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYD-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
      • Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
      • Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
      • Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
      • Jan 27, 2016: FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)
      • Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
      • Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
      • Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union
      • Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union
      • Oct 15, 2013: TWi Pharmaceuticals Comments on Dexilant Ruling
      • Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
      • Nov 17, 2011: Takeda Provides Update On DEXILANT Product Labeling
      • Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra Inc, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2017
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top